Assessment of circulating micrornas in plasma of lung cancer patients

Orazio Fortunato, Mattia Boeri, Carla Verri, Davide Conte, Mavis Mensah, Paola Suatoni, Ugo Pastorino, Gabriella Sozzi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer deaths worldwide and numerous ongoing research efforts are directed to identify new strategies for its early detection. The development of non-invasive blood-based biomarkers for cancer detection in its preclinical phases is crucial to improve the outcome of this deadly disease. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for cancer detection and prognosis definition, but lack of consensus on data normalization methods for circulating miRNAs and the critical issue of haemolysis, has affected the identification of circulating miRNAs with diagnostic potential. We describe here an interesting approach for profiling circulating miRNAs in plasma samples based on the evaluation of reciprocal miRNA levels measured by quantitative Real-Time PCR. By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value. In addition, to avoid bias due to the release of miRNAs from blood cells, a miRNA-ratios signature distinguishing haemolyzed samples was identified. The method described was validated in plasma samples of lung cancer patients, but given its reproducibility and reliability, could be potentially applied for the identification of diagnostic circulating miRNAs in other diseases.

Original languageEnglish
Pages (from-to)3038-3054
Number of pages17
JournalMolecules
Volume19
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

MicroRNAs
Lung Neoplasms
Plasmas
Tumor Biomarkers
Blood
Deregulation
Hemolysis
Tumors
Real-Time Polymerase Chain Reaction
Cause of Death
Blood Cells
Neoplasms
Cells
Monitoring

Keywords

  • Biomarkers
  • Early Diagnosis
  • Haemolysis
  • Lung Cancer
  • Mirnas
  • Real-Time Pcr

ASJC Scopus subject areas

  • Organic Chemistry
  • Medicine(all)

Cite this

Assessment of circulating micrornas in plasma of lung cancer patients. / Fortunato, Orazio; Boeri, Mattia; Verri, Carla; Conte, Davide; Mensah, Mavis; Suatoni, Paola; Pastorino, Ugo; Sozzi, Gabriella.

In: Molecules, Vol. 19, No. 3, 2014, p. 3038-3054.

Research output: Contribution to journalArticle

Fortunato, Orazio ; Boeri, Mattia ; Verri, Carla ; Conte, Davide ; Mensah, Mavis ; Suatoni, Paola ; Pastorino, Ugo ; Sozzi, Gabriella. / Assessment of circulating micrornas in plasma of lung cancer patients. In: Molecules. 2014 ; Vol. 19, No. 3. pp. 3038-3054.
@article{53092fb5aa9f4d399bf3da9e0ca0c6d3,
title = "Assessment of circulating micrornas in plasma of lung cancer patients",
abstract = "Lung cancer is the most common cause of cancer deaths worldwide and numerous ongoing research efforts are directed to identify new strategies for its early detection. The development of non-invasive blood-based biomarkers for cancer detection in its preclinical phases is crucial to improve the outcome of this deadly disease. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for cancer detection and prognosis definition, but lack of consensus on data normalization methods for circulating miRNAs and the critical issue of haemolysis, has affected the identification of circulating miRNAs with diagnostic potential. We describe here an interesting approach for profiling circulating miRNAs in plasma samples based on the evaluation of reciprocal miRNA levels measured by quantitative Real-Time PCR. By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value. In addition, to avoid bias due to the release of miRNAs from blood cells, a miRNA-ratios signature distinguishing haemolyzed samples was identified. The method described was validated in plasma samples of lung cancer patients, but given its reproducibility and reliability, could be potentially applied for the identification of diagnostic circulating miRNAs in other diseases.",
keywords = "Biomarkers, Early Diagnosis, Haemolysis, Lung Cancer, Mirnas, Real-Time Pcr",
author = "Orazio Fortunato and Mattia Boeri and Carla Verri and Davide Conte and Mavis Mensah and Paola Suatoni and Ugo Pastorino and Gabriella Sozzi",
year = "2014",
doi = "10.3390/molecules19033038",
language = "English",
volume = "19",
pages = "3038--3054",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Assessment of circulating micrornas in plasma of lung cancer patients

AU - Fortunato, Orazio

AU - Boeri, Mattia

AU - Verri, Carla

AU - Conte, Davide

AU - Mensah, Mavis

AU - Suatoni, Paola

AU - Pastorino, Ugo

AU - Sozzi, Gabriella

PY - 2014

Y1 - 2014

N2 - Lung cancer is the most common cause of cancer deaths worldwide and numerous ongoing research efforts are directed to identify new strategies for its early detection. The development of non-invasive blood-based biomarkers for cancer detection in its preclinical phases is crucial to improve the outcome of this deadly disease. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for cancer detection and prognosis definition, but lack of consensus on data normalization methods for circulating miRNAs and the critical issue of haemolysis, has affected the identification of circulating miRNAs with diagnostic potential. We describe here an interesting approach for profiling circulating miRNAs in plasma samples based on the evaluation of reciprocal miRNA levels measured by quantitative Real-Time PCR. By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value. In addition, to avoid bias due to the release of miRNAs from blood cells, a miRNA-ratios signature distinguishing haemolyzed samples was identified. The method described was validated in plasma samples of lung cancer patients, but given its reproducibility and reliability, could be potentially applied for the identification of diagnostic circulating miRNAs in other diseases.

AB - Lung cancer is the most common cause of cancer deaths worldwide and numerous ongoing research efforts are directed to identify new strategies for its early detection. The development of non-invasive blood-based biomarkers for cancer detection in its preclinical phases is crucial to improve the outcome of this deadly disease. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for cancer detection and prognosis definition, but lack of consensus on data normalization methods for circulating miRNAs and the critical issue of haemolysis, has affected the identification of circulating miRNAs with diagnostic potential. We describe here an interesting approach for profiling circulating miRNAs in plasma samples based on the evaluation of reciprocal miRNA levels measured by quantitative Real-Time PCR. By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value. In addition, to avoid bias due to the release of miRNAs from blood cells, a miRNA-ratios signature distinguishing haemolyzed samples was identified. The method described was validated in plasma samples of lung cancer patients, but given its reproducibility and reliability, could be potentially applied for the identification of diagnostic circulating miRNAs in other diseases.

KW - Biomarkers

KW - Early Diagnosis

KW - Haemolysis

KW - Lung Cancer

KW - Mirnas

KW - Real-Time Pcr

UR - http://www.scopus.com/inward/record.url?scp=84896920819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896920819&partnerID=8YFLogxK

U2 - 10.3390/molecules19033038

DO - 10.3390/molecules19033038

M3 - Article

VL - 19

SP - 3038

EP - 3054

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 3

ER -